Caranx Medical has announced the first clinical use of TAVIPILOT Soft, its artificial intelligence (AI)-driven intra-operative software which tracks real-time anatomical and instrument landmarks during transcatheter aortic valve implantation (TAVI).
The first procedures were performed at Clinique Pasteur (Toulouse, France) by Didier Tchétché and his team as part of the SAITO-1A first-in-human trial. This study includes 10 patients with severe aortic stenosis, all treated via the transfemoral approach using Sapien 3 (Edwards Lifesciences).
TAVIPILOT Soft was used without any technical issues in any the procedures, enabling autonomous identification of anatomical landmarks and accurate assessment of implantation depth, Caranx Medical said in a press release.
Comparative measurements between the TAVIPILOT Soft predicted valve positioning and the final implanted position selected by the investigator demonstrated an excellent accuracy of the software in all cases, the company press release adds, noting that no intra-procedural complications were reported.
“Our first clinical use of the TAVIPILOT Soft is a major achievement for the Caranx team. This study confirms the potential of real-time guidance in TAVI procedures to enhance precision and improve patient outcomes. We are excited to now move forward with early commercialisation expected by end 2025 and to provide interventional teams with a solution that can support safer and more predictable valve deployment,” says Eric Sejor, chief medical officer of Caranx Medical.
“Allowing a broader number of cardiologists and interventional cardiology centres to perform complex procedures, such as TAVI, the Caranx AI-driven software and autonomous robot is at the heart of our mission of entrepreneurs and business builders to save lives and revolutionise medicine” says Philippe Pouletty, founder of Caranx and chief executive officer of Truffle Capital.
